The Efficacy of Rivaroxaban in Reducing the Risk of Cardiovascular Events in Patients with Stable Ischemic Heart Disease and Peripheral Disease. Results of the COMPASS Trial
https://doi.org/10.18087/cardio.2018.3.10103
Abstract
The article considers modern approaches to the secondary prevention of cardiovascular events in patients with stable ischemic heart disease (IHD) and/or atherosclerosis of peripheral arteries (peripheral artery disease - PAD) with the oral anticoagulant rivaroxaban. The results of the first international prospective phase III study COMPASS for the evaluation of efficacy and safety of rivaroxaban including 27395 patients with stable IHD or PAD, are discussed. The results of the study were presented at European Congress of Cardiology 2017. Rivaroxaban reduced of the risk of cardiovascular death, stroke and myocardial infarction by 24%. The results of the study confirm the positive balance of risk/benefit and supplement the previously obtained data on the efficacy of rivaroxaban in patients with cardiovascular diseases.
About the Author
Nadezhda M. Savina
ФГБУ ДПО «Центральная государственная медицинская академия» УД Президента РФ
Russian Federation
Russian Federation
References
1. Fowkes F. G., Rudan D., Rudan I. et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382 (9901):1329-1340.
2. Anand S. S., Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003;41 (4):62-69.
3. Gent M., Beaumont D., Blanchard J. et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
4. Bhatt D. L., Fox K. A. A., Hacke W. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717.
5. Bonaca M. P., Bhatt D. L., Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-1800.
6. Hiatt W. R., Fowkes F. G. R., Heizer G. et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017;376:32-40.
7. Weitz J. I., Bates S. M. New anticoagulants. J Thromb Haemost 2005;3:1843-1853.
8. Bounameaux H. The novel anticoagulants: entering a new era. Swiss Med Wkly 2009;139 (5-6):60-64.
9. Gilyarevsky S. R. The ratio of pharmacological and clinical effects of oral anticoagulant as a criterion for selecting the optimal medicine for prolonged prevention of thromboembolism. Kardiologiya 2014;12:63-71. Russian (Гиляревский С. Р. Соотношение фармакологических и клинических эффектов перорального антикоагулянта как критерий выбора оптимального препарата для длительной профилактики тромбоэмболических осложнений. Кардиология 2014;12:63-71).
10. Mueck W., Lensing A. W., Agnelli G. et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50:675-686.
11. Ogilvie I. M., Newton N., Welner S. A. et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010;123 (7):638-645.
12. Sulimov V. A., Napalkov D. A., Sokolova A. A. Comparative efficiency and safety of new oral anticoagulants. Rational phar macotherapy in cardiology 2013;9 (4):433-438. Russian (Сулимов В. А., Напалков Д. А., Соколова А. А. Сравнительная эффективность и безопасность новых пероральных антикоагулянтов. Рациональная фармакотерапия в кардиологии 2013;9 (4):433-438).
13. Gong I. Y., Kim R. B. Importance of pharmacokinetic profile and variability as deter. minants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 2013;29 (7):S24-33.
14. Haas S., Bode C., Norrving B., Turpie A. G. Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vasc Health Risk Manag 2014;10:101-114.
15. Husted S., De Caterina R., Andreotti F. et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014;111 (5):781-782.
16. Renda G., De Caterina R. The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol 2013;59 (3-4):53-62.
17. Arjomand H., Cohen M., Ezekowitz M. D. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease. J Invasive Cardiol 2004;16 (5):271-278.
18. Anand S., Yusuf S., Xie C. et al. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007;357:217-227.
19. Eikelboom J. W., Connolly S.J., Bosch J. et al. COMPASS investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14):1319-1330.
20. Mega J. L., Braunwald E., Wiviott S. D. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9-19.
21. Bosch J., Eikelboom J. W., Connolly S.J. Rationale, design and base-line characteristics of participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial. Can J Cardiol 2017;33 (8):1027-1035.
22. Bhatt D. L., Cryer B. L., Contant C. F. et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010;363:1909-1917.
Review
For citations:
Savina N.M. The Efficacy of Rivaroxaban in Reducing the Risk of Cardiovascular Events in Patients with Stable Ischemic Heart Disease and Peripheral Disease. Results of the COMPASS Trial. Kardiologiia. 2018;58(3):94-100. (In Russ.) https://doi.org/10.18087/cardio.2018.3.10103
Views:
1263
Email this article 
Post a Comment 
